Results 51 to 60 of about 2,541 (178)

The Efficacy of Adding Pioglitazone to Insulin Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis

Journal of Pharmacoeconomics and Pharmaceutical Management, 2021
Objectives: The significant increase of type 2 diabetes and its complications in individuals requires developing new approaches to control this disease.
Majid Davari, Elahe Khorasani, Rahim Sarvari Shojaei, Ali Akbari Sari, Hamidreza Zakeri, Parisa Saiyarsarai   +5 more
doaj  

National and Individual‐Level Economic Burden of Local Corticosteroid Use and Concomitant Use of Multiple Local Corticosteroid Formulations—A Nationwide Cohort Study

Clinical &Experimental Allergy, EarlyView.
Kjell Erik Julius Håkansson, Jonas Bækdal, Inge Raadal Skov, Steven Arild Wuyts Andersen, Zarqa Ali, Anders Løkke, Rikke Ibsen, Ole Hilberg, Howraman Meteran, Claus Rikard Johnsen, Vibeke Backer, Charlotte Suppli Ulrik   +11 more
wiley   +1 more source

Value of Clinical Evidence and Health Economics and Outcomes Research (HEOR) Studies

Muscle &Nerve, Volume 73, Issue S1, Page S7-S12, February 2026.
ABSTRACT Randomized controlled trials (RCTs) remain the gold standard for establishing the efficacy and safety of new treatments. However, clinical evidence derived from the systematic analysis of real‐world data generated through routine clinical practice can complement RCT data by offering insights into treatment performance in broader, more ...
Agessandro Abrahao, Malgorzata Ciepielewska, Lorne Zinman   +2 more
wiley   +1 more source

Cost‐Effectiveness of Pembrolizumab Plus Trastuzumab and Chemotherapy Versus Trastuzumab Plus Chemotherapy as First‐Line Treatment of HER2‐Positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Cancer Medicine, Volume 14, Issue 22, November 2025.
ABSTRACT Objective This study aimed to evaluate the cost‐effectiveness of pembrolizumab in combination with trastuzumab and chemotherapy (PEM + TRAS + Chemo) as a first‐line treatment for patients with advanced HER2‐positive gastric or gastroesophageal junction (GEJ) adenocarcinoma from the perspective of the Chinese healthcare system. Methods Clinical
Yifang Liang, Yuyanzi Zhang, Hongfei Hu, Yan Li, Aixia Ma, Xin Guan   +5 more
wiley   +1 more source

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2628-2635, September 2025.
Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt, Áine Keogh, Linda Duane, John Ferguson, Anna Hobbins, Brian E. McGuire, Patrick Gillespie, Laurence J. Egan   +7 more
wiley   +1 more source

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis

Orphanet Journal of Rare Diseases, 2018
Background A Multi Criteria Decision Analysis (MCDA) technique was adopted to reveal the preferences of the Appraisal Body of the Polish HTA agency towards orphan drugs (OMPs).
Katarzyna Kolasa, Krzysztof Miroslaw Zwolinski, Vladimir Zah, Zoltán Kaló, Tadeusz Lewandowski   +4 more
doaj   +1 more source

Preregistration: A Key to Credible Real‐World Evidence Generation

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 9, September 2025.
ABSTRACT Background Preregistration of study protocols in a public repository promotes transparency and reproducibility in pharmacoepidemiological research. Despite its clear benefits, preregistration remains underutilized. Purpose Here, we discuss the advantages of preregistration, explore barriers to its implementation, and highlight existing ...
Emma Simonsen, Shirley V. Wang, Helene Kildegaard, Anton Pottegård   +3 more
wiley   +1 more source

Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co‐Design Approach With General Practitioners and Patients

Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 3, September 2025.
ABSTRACT Proton Pump Inhibitors (PPIs) are widely prescribed medications globally. PPIs are often inappropriately used – for example, prescribed without a clear indication, at higher‐than‐necessary doses, or for longer durations than needed – resulting in increased risks of adverse health outcomes such as nutrient deficiencies, osteoporosis‐related ...
Kristie Rebecca Weir, Clémentine Tombez, Yvonne Mattmann, Sofia C. Zambrano, Eliza Ferguson, Katharina Tabea Jungo, Martina Zangger, Shana Volken, Enriqueta Vallejo‐Yagüe, Renata Vidonscky Lüthold, Angela Edith Schulthess‐Lisibach, Christof Bieri, Michaela Barbier, Pascal Juillerat, Sven Streit, Jennifer Inauen   +15 more
wiley   +1 more source

Iranian Pharmaceutical Industry Opportunities in Iraq

Journal of Pharmacoeconomics and Pharmaceutical Management, 2019
Background: The socioeconomic and political situation of Iraq has provided a wide and open market. Because of the weak pharmaceutical industry and war, Iraq has a huge demand for pharmaceutical and medical services; this country is a reliable market in ...
Ahmed Hayder Mohsin Al Iami, Saman Zartab, Mona Jaberidoost, Alireza Yektadoost, Shekoufeh Nikfar, Abbas Kebriaeezadeh   +5 more
doaj  

Access to pediatric oncology medicine in Iran: a cross-sectional survey in Urmia

BMC Pediatrics
Background Cancer stands as a significant cause of mortality among children and adolescents, imposing a considerable burden on global healthcare. The World Health Organization (WHO) reports a stark imbalance in the accessibility of cancer medicines ...
Kiana Baghban, Sadra Nadimi Parashkouhi, Hadi Abbasian, Mehdi Varmaghani, Mehran Noroozi   +4 more
doaj   +1 more source